Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.

The global Fenofibrate market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Fenofibrate volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Fenofibrate market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Fenofibrate Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Tablet
Capsule

Segment by Application
Hospital
Drug Store

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
AbbVie
Lupin
Salix Pharmaceuticals
Vectura
Cipher Pharmaceuticals
Rhodes Pharmaceuticals
Impax Laboratories
Mylan
Teva
Sun Pharmaceutical
Bausch Health
HETERO
Aurobindo Pharma
Cipla
Amneal Pharmaceuticals
Prinston Pharmaceutical
Dr. Reddys Laboratories
APOTEX
Glenmark